Search

Your search keyword '"Vaduganathan, M."' showing total 885 results

Search Constraints

Start Over You searched for: Author "Vaduganathan, M." Remove constraint Author: "Vaduganathan, M."
885 results on '"Vaduganathan, M."'

Search Results

3. Heart failure medical therapy and outcomes in patients undergoing transcatheter mitral valve repair for secondary mitral regurgitation: a TVT Registry analysis across 449 US centers

4. Serial high-sensitivity troponin-I and long-term risk of myocardial infarction and coronary revascularization in subjects with suspected acute coronary syndrome

5. Effect of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction treated with beta-blockers: the DELIVER trial

6. Effects of dapagliflozin in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease: an analysis of the DELIVER trial

8. Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial

9. Influence of background therapy on efficacy of dapagliflozin in patients with heart failure and improved ejection fraction

10. Effect of dapagliflozin in patients in Asia with heart failure with mildly reduced or preserved ejection fraction: insights from DELIVER

12. Echocardiographic characterization of patients with supranormal ejection fraction: pooled core laboratory analysis of the TOPCAT and PARAGON-HF trials

13. Angiotensin–neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure

14. Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.

15. Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support–free days in patients hospitalized with COVID-19

16. Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial

17. In patients with type 2 diabetes chronic kidney disease is a modifiable cardiovascular risk factor

18. Association of baseline and longitudinal changes in cardiometabolic health with risk of heart failure among adults with type 2 diabetes: an analysis from the Look AHEAD trial

20. Serial high-sensitivity troponin T concentrations and long-term outcomes in patients with suspected acute coronary syndrome

21. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study

22. Greater event rates in high-risk patients with a history of heart disease: from the Systolic Blood Pressure Intervention Trial (SPRINT)

23. Multi-marker biomarker panel, adverse cardiovascular and kidney outcomes, and response to canagliflozin in the CANVAS Program

29. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure

37. Erratum: Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 (The Lancet (2018) 392(10159) (1736–1788)(S0140673618322037)(10.1016/S0140-6736(18)32203-7))

38. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017

39. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis

40. ESC/ESH guideline-recommended age categories and intensive blood pressure management in high-risk adults: insights from SPRINT

41. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019

42. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017

43. Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: Findings from the ASTRONAUT trial

44. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides

45. Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial

46. Mode of Death in Heart Failure With Preserved Ejection Fraction

47. Erratum: Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 (The Lancet (2018) 392(10159) (1923–1994), (S0140673618322256), (10.1016/S0140-6736(18)32225-6))

48. Medication dosing for heart failure with reduced ejection fraction — opportunities and challenges

Catalog

Books, media, physical & digital resources